Why the study?
Does moxonidine improve insulin sensitivity compared to atenolol in hypertensive obese postmenopausal women?
Does moxonidine improve insulin sensitivity compared to atenolol in hypertensive obese postmenopausal women?
The centrally acting sympatholytic agent moxonidine provides a more favorable metabolic profile regarding insulin resistance compared to atenolol in hypertensive postmenopausal women.
No takes yet. Share an insight, caveat, or question.
Moxonidine may be preferred over atenolol in insulin-resistant hypertensive postmenopausal women; extends metabolic benefit data for central sympatholytics.
Kaaja et al. (2007) studied this question.